Neurocrine Biosciences, Inc. (LON:0K6R)

Market Cap	10.04B -18.1%
Revenue (ttm)	2.13B +21.4%
Net Income	355.60M +40.2%
EPS	3.47 +41.9%
Shares Out	n/a
PE Ratio	28.24
Forward PE	17.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,287
Average Volume	1,648
Open	128.50
Previous Close	136.45
Day's Range	123.00 - 133.31
52-Week Range	84.36 - 161.05
Beta	0.28
RSI	45.83
Earnings Date	Feb 11, 2026

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 1,800
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K6R

Financial Performance

In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.

Financial numbers in USD